<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>150(7)</volume><submitter>Lin C</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Pain management following pediatric adenotonsillectomies is opioid-inclusive, leading to potential complications.&lt;h4>Objective&lt;/h4>To investigate the use of suprazygomatic maxillary nerve (SZMN) blocks to reduce pain and opioid use after pediatric intracapsular adenotonsillectomy and to measure recovery duration and incidence of complications.&lt;h4>Design, setting, and participants&lt;/h4>This was a randomized, blinded, prospective single-center tertiary pediatric hospital that included 60 pediatric patients (2-14 years old) scheduled for intracapsular adenotonsillectomy from November 2021 to March 2023. Patients were excluded for having combined surgical procedures, developmental delay, coagulopathy, chronic pain history, known or predicted difficult airway, or unrepaired co</pubmed_abstract><journal>JAMA otolaryngology-- head &amp; neck surgery</journal><pagination>564-571</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11117150</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Suprazygomatic Maxillary Nerve Blocks and Opioid Requirements in Pediatric Adenotonsillectomy: A Randomized Clinical Trial.</pubmed_title><pmcid>PMC11117150</pmcid><pubmed_authors>Sidell DR</pubmed_authors><pubmed_authors>Lin C</pubmed_authors><pubmed_authors>Thein J</pubmed_authors><pubmed_authors>Balakrishnan K</pubmed_authors><pubmed_authors>Tsui BCH</pubmed_authors><pubmed_authors>Zoghbi V</pubmed_authors><pubmed_authors>Abboud S</pubmed_authors><pubmed_authors>Meister KD</pubmed_authors><pubmed_authors>Kasimova K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Suprazygomatic Maxillary Nerve Blocks and Opioid Requirements in Pediatric Adenotonsillectomy: A Randomized Clinical Trial.</name><description>&lt;h4>Importance&lt;/h4>Pain management following pediatric adenotonsillectomies is opioid-inclusive, leading to potential complications.&lt;h4>Objective&lt;/h4>To investigate the use of suprazygomatic maxillary nerve (SZMN) blocks to reduce pain and opioid use after pediatric intracapsular adenotonsillectomy and to measure recovery duration and incidence of complications.&lt;h4>Design, setting, and participants&lt;/h4>This was a randomized, blinded, prospective single-center tertiary pediatric hospital that included 60 pediatric patients (2-14 years old) scheduled for intracapsular adenotonsillectomy from November 2021 to March 2023. Patients were excluded for having combined surgical procedures, developmental delay, coagulopathy, chronic pain history, known or predicted difficult airway, or unrepaired co</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2026-06-01T19:15:27.035Z</modification><creation>2026-05-21T03:08:47.474Z</creation></dates><accession>S-EPMC11117150</accession><cross_references><pubmed>38780948</pubmed><doi>10.1001/jamaoto.2024.1011</doi></cross_references></HashMap>